Medicus Pharma Secures $4.5M Through Debenture Issuance

Medicus Pharma Ltd ( (MDCX) ) has provided an announcement.

Medicus Pharma Ltd. entered into a securities purchase agreement with YA II PN, Ltd. on May 2, 2025, for the issuance and sale of debentures totaling up to $5,000,000. By June 17, 2025, the company had issued three debentures, with Yorkville purchasing them for net proceeds of $4,500,000. The debentures, guaranteed by the company’s subsidiaries, accrue interest at an annual rate of 8.00%, potentially increasing to 18.00% in case of default, and will mature on February 2, 2026.

The most recent analyst rating on (MDCX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.

Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a company incorporated under the laws of the Province of Ontario, Canada, operating in the pharmaceutical industry. The company focuses on issuing and selling debentures as part of its financial operations.

Average Trading Volume: 213,102

Current Market Cap: $41.11M

Learn more about MDCX stock on TipRanks’ Stock Analysis page.